CAPR Court News: Capricor Therapeutics Securities Fraud Class Action Filed After Clinical Data Issues and 64% Stock Drop – Contact BFA Law Before September 28

Impact · against what's priced in

Capricor Therapeutics faces severe devaluation as a securities fraud lawsuit follows the near-total collapse of its lead asset, Deramiocel. The combined impact of a negative FDA advisory committee vote, allegations of statistical manipulation, and a prior Complete Response Letter fundamentally undermines the company's valuation.

CAPR−0.90

No priced-in read yet